Veradermics (MANE) Non Operating Income (2025 - 2026)

Veradermics' (MANE) quarterly Non Operating Income came in at $2.6 million in Q1 2026, up 410.68% YoY from $515000.0 in Q1 2025, and up 410.68% on a QoQ basis from $515000.0 in Q1 2025.

Veradermics (MANE) Non Operating Income (2025 - 2026) Analysis & Trends

Veradermics (MANE) has 2 years of Non Operating Income data on file, last reported at $2.6 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Op. Inc. (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 234.30 Mn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -139.24 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn -
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 12.40
7 Royalty Pharma 33.72 Bn 35.84 Bn - -51.63 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -53.64 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 Veradermics 4.70 Bn 4.70 Bn - 6.05 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 6.05 Mn
Mar 31, 2026 2.63 Mn
Mar 31, 2025 515,000.00